Protein kinase C alpha (PKCα) (PKCα)

Protein kinase C alpha (PKCα) is a member of the conventional PKC subfamily of serine/threonine kinases, encoded by the PRKCA gene [2, 6]. It is ubiquitously expressed and serves as a critical signaling hub, integrating signals from various cell surface receptors to regulate fundamental processes such as cell proliferation, apoptosis, differentiation, and motility [2, 4, 9]. PKCα is uniquely regulated by the second messengers calcium and diacylglycerol (DAG), which trigger its translocation from the cytosol to cellular membranes where it phosphorylates a wide array of substrates [2, 10]. In the context of disease, PKCα exhibits a complex, context-dependent role; it is often overexpressed and acts as an oncogene in cancers like breast and bladder cancer, yet it can function as a tumor suppressor in colorectal and renal cancers [1, 2, 7]. Beyond oncology, PKCα is a key regulator of cardiac contractility and has been implicated in the pathogenesis of heart failure, atherosclerosis, and neurodegenerative conditions such as Alzheimer's disease [2, 3, 9]. Therapeutic efforts have targeted PKCα using small-molecule inhibitors, antisense oligonucleotides like aprinocarsen, and natural product modulators like bryostatin 1 [2, 7, 10]. However, the development of effective therapies has been hindered by the challenge of achieving isoform selectivity and the potential for adverse effects due to the enzyme's broad physiological roles [1, 2].

Other names

PRKCA [6, 8]PKCA [8, 11]PKC-alpha [6, 8, 11]PRKACA [6, 8]AAG6 [6, 8, 14]Protein kinase C alpha type [8, 11]

ATP-competitive inhibition, antisense-mediated mRNA degradation, allosteric modulation, and diacylglycerol (DAG) mimicry/activation [1, 2, 10]